Fungicidal Synergism of Fluconazole and Cyclosporine in Candida albicans Is Not Dependent on Multidrug Efflux Transporters Encoded by the CDR1 , CDR2 , CaMDR1 , and FLU1 Genes
Open Access
- 1 May 2003
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 47 (5) , 1565-1570
- https://doi.org/10.1128/aac.47.5.1565-1570.2003
Abstract
The combination of fluconazole (FLC) and cyclosporine (CY) is fungicidal in FLC-susceptible C. albicans (O. Marchetti, P. Moreillon, M. P. Glauser, J. Bille, and D. Sanglard, Antimicrob. Agents Chemother. 44:2373-2381, 2000). The mechanism of this synergism is unknown. CY has several cellular targets including multidrug efflux transporters. The hypothesis that CY might inhibit FLC efflux was investigated by comparing the effect of FLC-CY in FLC-susceptible parent CAF2-1 (FLC MIC, 0.25 mg/liter) and in FLC-hypersusceptible mutant DSY1024 (FLC MIC, 0.03 mg/liter), in which the CDR1, CDR2, CaMDR1, and FLU1 transporter genes have been selectively deleted. We postulated that a loss of the fungicidal effect of FLC-CY in DSY1024 would confirm the roles of these efflux pumps. Time-kill curve studies showed a more potent fungistatic effect of FLC (P = 0.05 at 48 h with an inoculum of 103 CFU/ml) and a more rapid fungicidal effect of FLC-CY (P = 0.05 at 24 h with an inoculum of 103 CFU/ml) in the FLC-hypersusceptible mutant compared to those in the parent. Rats with experimental endocarditis were treated for 2 or 5 days with high-dose FLC, high-dose CY, or both drugs combined. FLC monotherapy for 5 days was more effective against the hypersusceptible mutant than against the parent. However, the addition of CY to FLC still conferred a therapeutic advantage in animals infected with mutant DSY1024, as indicated by better survival (P = 0.04 versus the results obtained with FLC) and sterilization of valves and kidneys after a very short (2-day) treatment (P = 0.009 and 0.002, respectively, versus the results obtained with FLC). Both in vitro and in vivo experiments consistently showed that the deletion of the four membrane transporters in DSY1024 did not result in loss of the fungicidal effect of FLC-CY. Yet, the accelerated killing in the mutant suggested a “dual-hit” mechanism involving FLC hypersusceptibility due to the efflux pump elimination and fungicidal activity conferred by CY. Thus, inhibition of multidrug efflux transporters encoded by CDR1, CDR2, CaMDR1, and FLU1 genes is not responsible for the fungicidal synergism of FLC-CY. Other cellular targets must be considered.Keywords
This publication has 31 references indexed in Scilit:
- Calcineurin is essential for survival during membrane stress in Candida albicansThe EMBO Journal, 2002
- Sensitive Bioassay for Determination of Fluconazole Concentrations in Plasma Using a Candida albicans Mutant Hypersusceptible to AzolesAntimicrobial Agents and Chemotherapy, 2001
- Practice Guidelines for the Treatment of CandidiasisClinical Infectious Diseases, 2000
- Clinical Significance of Nephrotoxicity in Patients Treated with Amphotericin B for Suspected or Proven AspergillosisClinical Infectious Diseases, 1999
- Liposomal Amphotericin B for Empirical Therapy in Patients with Persistent Fever and NeutropeniaNew England Journal of Medicine, 1999
- Occurrence of yeast bloodstream infections between 1987 and 1995 in five Dutch university hospitalsEuropean Journal of Clinical Microbiology & Infectious Diseases, 1996
- The Mechanism of Action of Cyclosporin A and FK506Clinical Immunology and Immunopathology, 1996
- A Randomized Trial Comparing Fluconazole with Amphotericin B for the Treatment of Candidemia in Patients without NeutropeniaNew England Journal of Medicine, 1994
- Secular Trends in the Epidemiology of Nosocomial Fungal Infections in the United States, 1980-1990The Journal of Infectious Diseases, 1993
- Cyclosporin partitions into phospholipid vesicles and disrupts membrane architectureImmunology Letters, 1985